Chemomab Therapeutics (CMMB) SC 13D/A Anchiano Therapeutics Ltd.

Exhibit 99.8

Joint Filing Agreement

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (and any amendments thereto) with respect to the Ordinary Shares and American Depositary Shares, each of which represents five Ordinary Shares, evidenced by American Depositary Receipts, beneficially owned by each of them, of Anchiano Therapeutics Ltd., a corporation incorporated under the laws of the State of Israel. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 31^st day of December, 2019.

ACCESS INDUSTRIES HOLDINGS LLC	/s/ Alejandro Moreno
	Alejandro Moreno

ACCESS INDUSTRIES MANAGEMENT, LLC	/s/ Alejandro Moreno
	Alejandro Moreno

ACCESS INDUSTRIES, LLC	/s/ Alejandro Moreno
	Alejandro Moreno

CLAL BIOTECHNOLOGY INDUSTRIES LTD.	/s/ Ofer Gonen
	Ofer Gonen
	/s/ Assaf Segal
	Assaf Segal
	*
	Len Blavatnik

* The undersigned, by signing his name hereto, executes this Joint Filing Agreement pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

By:	/s/ Alejandro Moreno
	Name: Alejandro Moreno
	Attorney-in-Fact